Safety of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease (IBD)

• Status: Completed
• Trial end date: 2016-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This study aims to test the hypothesis that the accelerated infusion of infliximab is not inferior to the conventional 2 hour infusion with respect to the frequency of infusion reaction.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Asan Medical Center
• Treatments: Infliximab

Criteria

Inclusion Criteria:

• Patients receiving infliximab for Crohn's disease or ulcerative colitis

• Ethnicity: Korean

• Patients who did not show any infusion reactions during 4 times of infliximab (5mg/kg) infusions for 2 hours

• Informed consents

Exclusion Criteria:

• Sever cardiopulmonary diseases

• Allergic diseases

• Bronchial asthma

• Allergic rhinitis

• Atopic dermatitis

• Other allergic diseases determined not suitable for study participation by investigators

• Severe liver disease

• Severe renal disease

• Body weight over 100 kg

• Other medical or surgical disease determined not suitable for study participation by investigators